|
As posted on StreetInsider.com
October 28, 2009 12:43 PM EDT (post cc) "National Securities initiates coverage on Dyax (Nasdaq: DYAX) with a Buy. Price target $5. Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications." Sentiment : Strong Buy Rating :
 (1 Rating) |
Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.04